<DOC>
	<DOCNO>NCT00353574</DOCNO>
	<brief_summary>This research study new experimental drug call darusentan . Darusentan currently approve United States ( U.S. ) Food Drug Administration ( FDA ) use U.S. , mean doctor prescribe drug . The purpose study evaluate long-term safety darusentan subject resistant systolic hypertension despite treatment full dos three antihypertensive medication , include diuretic .</brief_summary>
	<brief_title>DORADO-EX : Long-Term Safety Extension Study Phase 3 DORADO Study ( Protocol DAR-311 ) Darusentan Resistant Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LU 135252</mesh_term>
	<criteria>Subjects complete Treatment Period clinical trial DAR311 Receiving adhere full dos appropriate guidelinerecommended antihypertensive drug three different class antihypertensive agent , include diuretic Subjects discontinue treatment study drug prior end Treatment Period DAR311 due study drugrelated adverse event ( AE ) Treatment another endothelin receptor antagonist within 6 month study entry</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Resistant Hypertension</keyword>
</DOC>